Kraig Biocraft Laboratories Signs Landmark Collaborative Agreement with Government Agency in Southeast Asia to Advance Spider Silk Production
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has signed a significant multi-year agreement with a Southeast Asian government agency to advance its spider silk production capabilities.
The collaboration provides Kraig Labs with access to government-supported rearing facilities, technical personnel, and infrastructure essential for scaling up production and expanding operational capacity. The company plans to initiate operations at the new facility in early August 2025.
This strategic partnership represents the culmination of years of groundwork and positions the company to accelerate its path toward large-scale commercialization of next-generation biomaterials.
Kraig Biocraft Laboratories (OTCQB: KBLB), un'azienda biotecnologica specializzata nella tecnologia della seta di ragno, ha firmato un importante accordo pluriennale con un'agenzia governativa del Sud-est asiatico per potenziare le sue capacità di produzione di seta di ragno.
La collaborazione offre a Kraig Labs l'accesso a strutture di allevamento supportate dal governo, personale tecnico e infrastrutture fondamentali per aumentare la produzione e ampliare la capacità operativa. L'azienda prevede di avviare le attività presso la nuova struttura a inizio agosto 2025.
Questa partnership strategica rappresenta il risultato di anni di preparativi e posiziona l'azienda per accelerare il percorso verso la commercializzazione su larga scala di biomateriali di nuova generazione.
Kraig Biocraft Laboratories (OTCQB: KBLB), una empresa biotecnológica especializada en tecnología de seda de araña, ha firmado un importante acuerdo plurianual con una agencia gubernamental del sudeste asiático para avanzar en sus capacidades de producción de seda de araña.
La colaboración proporciona a Kraig Labs acceso a instalaciones de cría apoyadas por el gobierno, personal técnico e infraestructura esenciales para ampliar la producción y expandir la capacidad operativa. La empresa planea iniciar operaciones en la nueva instalación a principios de agosto de 2025.
Esta asociación estratégica representa la culminación de años de trabajo previo y posiciona a la empresa para acelerar su camino hacia la comercialización a gran escala de biomateriales de próxima generación.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 거미줄 기술을 전문으로 하는 생명공학 회사로, 동남아시아 정부 기관과 다년간의 중요한 협약을 체결하여 거미줄 생산 능력을 향상시키기로 했습니다.
이번 협력을 통해 Kraig Labs는 정부 지원 사육 시설, 기술 인력 및 인프라에 접근할 수 있게 되어 생산 규모를 확대하고 운영 능력을 확장할 수 있습니다. 회사는 2025년 8월 초에 새로운 시설에서 운영을 시작할 계획입니다.
이 전략적 파트너십은 수년간의 준비 작업의 결실이며, 차세대 생체재료의 대규모 상업화로 가는 길을 가속화하는 데 회사의 위치를 확고히 합니다.
Kraig Biocraft Laboratories (OTCQB : KBLB), une entreprise de biotechnologie spécialisée dans la technologie de la soie d'araignée, a signé un accord pluriannuel important avec une agence gouvernementale d'Asie du Sud-Est pour développer ses capacités de production de soie d'araignée.
Cette collaboration offre à Kraig Labs l'accès à des installations d'élevage soutenues par le gouvernement, du personnel technique et des infrastructures essentiels pour augmenter la production et étendre la capacité opérationnelle. L'entreprise prévoit de démarrer les opérations dans la nouvelle installation début août 2025.
Ce partenariat stratégique représente l'aboutissement de plusieurs années de préparation et positionne l'entreprise pour accélérer sa trajectoire vers la commercialisation à grande échelle de biomatériaux de nouvelle génération.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein Biotechnologieunternehmen, das sich auf Spinnenseidentechnologie spezialisiert hat, hat eine bedeutende mehrjährige Vereinbarung mit einer Regierungsbehörde in Südostasien unterzeichnet, um seine Produktionskapazitäten für Spinnenseide auszubauen.
Die Zusammenarbeit ermöglicht Kraig Labs den Zugang zu staatlich geförderten Zuchtanlagen, technischem Personal und Infrastruktur, die für die Skalierung der Produktion und Erweiterung der Betriebskapazitäten unerlässlich sind. Das Unternehmen plant, den Betrieb in der neuen Einrichtung Anfang August 2025 aufzunehmen.
Diese strategische Partnerschaft stellt den Höhepunkt jahrelanger Vorarbeit dar und positioniert das Unternehmen, um den Weg zur großflächigen Kommerzialisierung von Biomaterialien der nächsten Generation zu beschleunigen.
- Access to government-supported rearing facilities and infrastructure
- Technical personnel support from government agency
- Accelerated path to large-scale commercialization
- Immediate timeline for facility operations (August 2025)
- No specific financial terms or economic impact disclosed
- Exact location and partner agency in Southeast Asia not specified
ANN ARBOR, Mich., July 28, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced the formal signing of a multi-year agreement with a government agency in Southeast Asia to support the scale-up of its recombinant spider silk production.
This agreement is the result of many years of groundwork by Kraig Labs and marks a significant step in the Company's ongoing efforts to commercialize next-generation biomaterials. Under the terms of the agreement, Kraig Labs will gain access to government-supported rearing facilities, technical personnel, and infrastructure critical to accelerating production and expanding operational capacity.
"This milestone reflects many years of work by our senior management and on-the-ground team," said COO of Kraig Labs, Jon Rice. "With the support of this agreement, we are now positioned to move more quickly and efficiently toward large-scale commercialization."
Kraig Labs expects to take possession of the new facility and initiate operations in early August.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the new partnership announced by Kraig Biocraft Laboratories (KBLB)?
When will KBLB begin operations at the new Southeast Asian facility?
What resources will the government agency provide to KBLB under this agreement?
How will this partnership impact KBLB's commercialization plans?
What is Kraig Biocraft Laboratories' main technology focus?
